NCT00700947

Using Beta Blockers to Treat Mitral Regurgitation

Beta-Blockade in Chronic Mitral Regurgitation: Moving From the Laboratory Experiment to Clinical Investigation

• Status: Terminated
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 27 (actual)
• Sponsor: Wake Forest University Health Sciences · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study tests whether beta-blocker will benefit asymptomatic patients with chronic primary mitral regurgitation.

Detailed description

The purpose of this study tests 1) whether Toprol xl, a beta-blocker will benefit asymptomatic patients with chronic primary mitral regurgitation; 2) investigate the effects of chronic mitral regurgitation on left ventricular remodeling, left ventricular function,exercise capacity and clinical symptoms.

Conditions

• Heart Disease
• Mitral Regurgitation
• Heart Valve Disease
• Mitral Valve Insufficiency

Interventions

Type	Name	Description
DRUG	Beta-blocker therapy (TOPROL-XL® )	Patients who are asymptomatic with normal left ventricular systolic function and wish to be medically treated for severe primary mitral regurgitation with Beta-blocker.

Timeline

• Start date: 2007-10-01
• Primary completion: 2009-06-01
• Completion: 2009-09-01
• First posted: 2008-06-19
• Last updated: 2018-08-14

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study